ViaScint

ViaScint®

Imaging A formulation of I123-iodophenyl pentadecanoic acid used to evaluate post-CABG myocardium. See CABG.
References in periodicals archive ?
NDAs for BiDil, a treatment for congestive heart failure, and ViaScint, a novel cardiac imaging agent, were filed in 1996.
AMEX: MRE) today announced the filing of a New Drug Application (NDA) for its novel imaging agent VIASCINT (123I-Iodophenylpentadecanoic acid) with the U.
Clinical trial results indicate that VIASCINT is a safe and easy-to-use radiopharmaceutical, and that the compound is well suited for imaging cardiac metabolism.
ViaScint Phase III clinical trials were completed, and the results support its utility in predicting the functional outcome of coronary artery bypass graft (CABG) surgery;
The 1996 highlights should include a growing royalty revenue stream, the submission of New Drug Applications (NDAs) for BiDil and ViaScint, and the acquisition of strategic new products.
Data from the ViaScint studies are being analyzed, and plans are underway to conduct the pivotal Bidil bioequivalence study.
ViaScint (I-123-iodophenylpentadecanoic acid; IPPA) is a radioactive fatty acid derivative under development by Medco Research to provide a widely available and cost-effective alternative to PET scanning (positron emission tomography) of the heart.
By contrast, ViaScint imaging requires about 30 minutes and is used with less costly SPECT scanning (single- photon emission computed tomography) which is available at most large hospitals and cardiac diagnostic centers.